← board
ELTP
distress 0/10 · well-funded / low risk$0.38+2%today-47% from 52w high
Lead: anticoagulant
Revenue
$149M
Liquidity
$30M
Runway
—
Shares 1y
+1%
Price & events
-17.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+2.4%
1D
-5.2%
1W
+5.3%
1M
+5.3%
3M
-15.8%
6M
-31.1%
1Y
+99.5%
2Y
+658.0%
5Y
+658.0%
All
Overview
- Market Cap
- $408.26M
- Volume
- 250
- 52 Week Range
- $0.34 – $0.71
- Total Shares
- 1.08B
- Float Shares
- 836.04M
- % Held by Insiders
- 22.38%
- % Held by Institutions
- 0.00%
- RVOL
- 0.00x
- Beta
- 0.38
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2026-08-14Estimated 45%earningsEarningsEarnings releaseyahoo
- June 1, 2026regulatory submissionFiled (NDA/BLA)unspecified generic anticoagulant · Filed an Abbreviated New Drug Application (ANDA) with the FDA for a generic anticoagulant drug.SEC 8-K
- February 18, 2026 at 11:30 AM ESTconferencedata presentationsecondaryConference call to discuss Q3 fiscal 2026 financial results and provide business update.SEC 8-K
- Monday, November 17, 2025conferencedata presentationsecondaryConference call to discuss Q2 FY2026 financial results and provide corporate update.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 1,077,196,442 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — anticoagulant
- none identified
Recent news
- 2026-07-16Elite Pharmaceuticals, Inc. (ELTP) News, Articles, Events & Latest Updates - Stocktwits
- 2026-07-10Elite Pharmaceuticals (ELTP) Q4 2025 earnings summary - Quartr
- 2026-07-04Price to earnings forward of Elite Pharmaceuticals, Inc. – OTC:ELTP - TradingView
- 2026-07-01Elite Pharmaceuticals (OTCPK:ELTP) Stock Faces Earnings Quality Questions After TTM Profitability Reached - simplywall.st
- 2026-07-01Elite Pharmaceuticals (ELTP) Reports Strong Q4 Fiscal 2026 Earni - GuruFocus
- 2026-06-29Elite Pharmaceuticals (ELTP) Reports Strong Revenue Growth and P - GuruFocus
- 2026-06-29ELTP: Record revenue and net income growth from new launches, but risks remain from competition and customer concentration - TradingView
- 2026-06-29Elite Pharmaceuticals (OTC: ELTP) revenue jumps 77% in fiscal 2026 - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.